Biological progress and clinical research status of disialoganglioside and its related antibodies with pediatric solid tumors
10.3760/cma.j.cn101070-20230727-00035
- VernacularTitle:双唾液酸神经节苷脂及其相关抗体与儿童实体肿瘤的生物学进展和临床研究现状
- Author:
Chiyi JIANG
1
;
Yan SU
Author Information
1. 国家儿童医学中心，首都医科大学附属北京儿童医院肿瘤内科，儿童肿瘤发病机制与创新药物研究联合实验室，儿科重大疾病研究教育部重点实验室，北京 100045
- Keywords:
Child;
Solid tumor;
Disialoganglioside;
Immunotherapy;
Anti-GD2 monoclonal antibody
- From:
Chinese Journal of Applied Clinical Pediatrics
2024;39(9):701-706
- CountryChina
- Language:Chinese
-
Abstract:
Current treatment modalities for pediatric solid tumors include chemotherapy, surgery, transplantation, radiotherapy, etc.Despite the positive development of multidisciplinary treatment, the long-term prognosis of children with high-risk metastatic and/or recurrent malignant tumors remains challenging.Disialoganglioside (GD2), a tumor-associated antigen, is one of the main ideal targets for cancer immunotherapy.In recent years, immunotherapy with anti-GD2 monoclonal antibodies has been gradually applied in the clinical diagnosis and treatment of high-risk neuroblastoma, osteosarcoma, soft tissue sarcoma and other pediatric tumors.This article reviews the biological relationship between GD2 and pediatric solid tumors and the clinical research status of anti-GD2 immunotherapy, to provide theoretical and practical evidence for the diagnosis and treatment of various pediatric malignant solid tumors in China.
